Simplify the Development and Implementation of Diagnostic Testing in European Laboratories

Many laboratories around the world have adopted expanded diagnostic testing capabilities to address the coronavirus pandemic and are now seeking ways to expand testing with additional workflows for infectious disease syndromic panels, pharmacogenomic analysis, oncology testing, and more. 

Historically, developing a molecular test within a clinical laboratory has been perceived as a complicated and laborious process. In this webinar, we aim to dispel common misconceptions of in-house devices (IHD*) (also known as in-house test or in-house assay (IHA)) by providing a comprehensive overview of what it takes for a clinical laboratory to establish an in-house assay (IHA) in their laboratory.
 
Learning Objectives
• Describe different types of in vitro diagnostic (IVD) tests
• Identify differences between an in-house device (IHD) and an IVD test
• List the benefits of running IHDs and IVD tests

 

*For simplification we are using the term "IVD assay" to describe CE-IVD assays and "IHD" to describe in-house developed IVD assays.